ECSP14033371A - Composiciones farmacéuticas y tratamiento de mastitis - Google Patents

Composiciones farmacéuticas y tratamiento de mastitis

Info

Publication number
ECSP14033371A
ECSP14033371A ECIEPI201433371A ECPI201433371A ECSP14033371A EC SP14033371 A ECSP14033371 A EC SP14033371A EC IEPI201433371 A ECIEPI201433371 A EC IEPI201433371A EC PI201433371 A ECPI201433371 A EC PI201433371A EC SP14033371 A ECSP14033371 A EC SP14033371A
Authority
EC
Ecuador
Prior art keywords
mastitis
treatment
pharmaceutical compositions
pharmaceutical composition
relates
Prior art date
Application number
ECIEPI201433371A
Other languages
English (en)
Inventor
Heinz-Georg Wetzstein
Wolfgang Wiehl
Robrecht Froyman
Kristine Fraatz
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48672650&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14033371(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of ECSP14033371A publication Critical patent/ECSP14033371A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica y a procedimientos de tratamiento y/o prevención de mastitis en mamíferos no humanos. Más en particular, la presente invención se refiere al tratamiento de mastitis en vacas. La composición farmacéutica comprende una mezcla de un ácido fosfónico y al menos un agente antimicrobiano.
ECIEPI201433371A 2012-06-29 2014-12-29 Composiciones farmacéuticas y tratamiento de mastitis ECSP14033371A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261666312P 2012-06-29 2012-06-29

Publications (1)

Publication Number Publication Date
ECSP14033371A true ECSP14033371A (es) 2015-09-30

Family

ID=48672650

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201433371A ECSP14033371A (es) 2012-06-29 2014-12-29 Composiciones farmacéuticas y tratamiento de mastitis

Country Status (23)

Country Link
US (1) US10265330B2 (es)
EP (1) EP2866812B1 (es)
JP (1) JP6246804B2 (es)
KR (1) KR20150030707A (es)
CN (2) CN110522914A (es)
AR (1) AR091603A1 (es)
AU (1) AU2013283375B2 (es)
BR (1) BR112014031866A2 (es)
CA (1) CA2877794C (es)
CL (1) CL2014003503A1 (es)
CO (1) CO7240376A2 (es)
CR (1) CR20140594A (es)
DO (1) DOP2014000300A (es)
EC (1) ECSP14033371A (es)
HK (1) HK1206623A1 (es)
IL (1) IL235768A0 (es)
MX (1) MX368153B (es)
NZ (1) NZ702087A (es)
PE (1) PE20150199A1 (es)
PH (1) PH12014502864A1 (es)
RU (1) RU2659430C2 (es)
WO (1) WO2014001353A1 (es)
ZA (1) ZA201500649B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8757092B2 (en) 2011-03-22 2014-06-24 Eco-Composites Llc Animal bedding and associated method for preparing the same
US9737047B2 (en) 2011-03-22 2017-08-22 Ccd Holdings Llc Method for the treatment, control, minimization, and prevention of bovine mastitis
AU2013283375B2 (en) 2012-06-29 2018-04-26 Elanco Animal Health Gmbh Pharmaceutical compositions and treatment of mastitis
MX375254B (es) * 2013-02-08 2025-03-06 Luoda Pharma Ltd Una composición antimicrobiana farmacéutica o veterinaria intramamaria que comprende un poliéter ionóforo, o un uso de la misma para tratar mastitis.
EP2970586B1 (en) 2013-03-15 2022-12-07 Genzyme Corporation Amine functional polyamides
BR112016005795B1 (pt) 2013-09-16 2022-07-12 Zoetis Services Llc Conjunto de infusão
JP2016088918A (ja) * 2014-11-11 2016-05-23 大山乳業農業協同組合 乳房炎治療・予防用組成物、並びに、乳房炎の治療・予防方法
PL3124016T3 (pl) * 2015-07-31 2020-04-30 Warszawski Uniwersytet Medyczny Przeciwłuszczycowa kompozycja emulsyjna zawierająca cefazolinę
US10772900B2 (en) * 2016-07-27 2020-09-15 The Trustees Of The University Of Pennsylvania Drug target for treating veterinary infections and methods of using same
KR102978287B1 (ko) * 2019-07-11 2026-06-17 가부시키가이샤 세렌 파머 프로토테카증의 신규 치료제
ES3058367T3 (es) 2020-12-24 2026-03-10 Intervet Int Bv Un compuesto antimicrobiano de ortosomicina para su uso en métodos de tratamiento de mastitis
RU2762088C1 (ru) * 2021-05-05 2021-12-15 Федеральное государственное бюджетное научное учреждение "Всероссийский научно-исследовательский ветеринарный институт патологии, фармакологии и терапии" (ФГБНУ "ВНИВИПФиТ") Способ лечения мастита у коров
CN113368043A (zh) * 2021-06-11 2021-09-10 吉林大学 一种复方阿莫西林乳房注入剂及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4034099A (en) * 1974-03-29 1977-07-05 The Upjohn Company Compositions and method for treating mastitis in milk animals
US4210635A (en) * 1978-02-15 1980-07-01 Fujisawa Pharmaceutical Co., Ltd. Antibacterial composition
US4330529A (en) * 1978-02-15 1982-05-18 Fujisawa Pharmaceutical Co., Ltd. Antibacterial composition
JPS62129217A (ja) 1985-12-02 1987-06-11 Fujisawa Pharmaceut Co Ltd 医薬用殺菌組成物
NZ503027A (en) * 1997-07-29 2002-10-25 Kaneka Corp Use of rifamycin derivative for treating mastitis in a domestic animal
AU2004258746A1 (en) * 2003-07-31 2005-02-03 Pharmacia & Upjohn Company Llc Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
DE102004054873A1 (de) * 2004-11-12 2006-05-18 Bayer Healthcare Ag Behandlung von Mastitis
EP2018864A1 (en) 2007-07-23 2009-01-28 Biomet Deutschland GmbH Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition
CN101744827B (zh) 2008-12-15 2012-05-30 天津中敖生物科技有限公司 治疗鸡大肠杆菌的药物组合物及其制备方法、应用
US8449916B1 (en) * 2009-11-06 2013-05-28 Iowa State University Research Foundation, Inc. Antimicrobial compositions and methods
EP2404601A1 (en) 2010-07-06 2012-01-11 BioAgency AG New drug combinations for the treatment of Malaria
CN101879172B (zh) 2010-07-13 2012-07-18 杨建彬 头孢噻呋钠复方制剂
EA021846B1 (ru) 2011-05-11 2015-09-30 ЛИМОНОВ, Виктор Львович Фармацевтическая композиция антибактериального действия для парентерального применения, способ ее получения
AU2013283375B2 (en) 2012-06-29 2018-04-26 Elanco Animal Health Gmbh Pharmaceutical compositions and treatment of mastitis

Also Published As

Publication number Publication date
MX2014015631A (es) 2015-04-09
CA2877794A1 (en) 2014-01-03
EP2866812A1 (en) 2015-05-06
RU2015102562A (ru) 2016-08-20
CO7240376A2 (es) 2015-04-17
BR112014031866A2 (pt) 2022-02-01
JP2015521644A (ja) 2015-07-30
CR20140594A (es) 2015-02-06
US20150164926A1 (en) 2015-06-18
ZA201500649B (en) 2025-10-29
WO2014001353A1 (en) 2014-01-03
CA2877794C (en) 2020-08-04
JP6246804B2 (ja) 2017-12-13
HK1206623A1 (en) 2016-01-15
AU2013283375A1 (en) 2014-12-18
CN104379151A (zh) 2015-02-25
CN110522914A (zh) 2019-12-03
PE20150199A1 (es) 2015-01-31
RU2659430C2 (ru) 2018-07-02
AR091603A1 (es) 2015-02-18
US10265330B2 (en) 2019-04-23
CL2014003503A1 (es) 2015-05-04
AU2013283375B2 (en) 2018-04-26
NZ702087A (en) 2016-12-23
KR20150030707A (ko) 2015-03-20
EP2866812B1 (en) 2017-10-04
DOP2014000300A (es) 2015-07-15
MX368153B (es) 2019-09-20
PH12014502864A1 (en) 2015-02-23
IL235768A0 (en) 2015-01-29

Similar Documents

Publication Publication Date Title
DOP2014000300A (es) Composiciones farmacéuticas y tratamiento de mastitis
MX2013003365A (es) Composicion farmaceutica.
PH12016501807A1 (en) Novel compounds
AR081681A1 (es) METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA
WO2015023976A3 (en) Selective grp94 inhibitors and uses thereof
BR112015011430A2 (pt) composição para liberação imediata e prolongada
NZ708821A (en) Lfa-1 inhibitor formulations
TN2015000371A1 (en) Substituted imidazopyridazines
CO6741223A2 (es) Derivados de azetidina útiles para el tratamiento de enfermedades metabólicas e inflamatorias
BR112014032759A2 (pt) composições lipídicas de racecadotril
PH12016500054A1 (en) Substituted pyrazolo-pyridinamines
UA105260C2 (ru) Фармацевтическая композиция для приготовления инфузионных растворов антимикробных препаратов, способ ее получения (варианты)
JOP20190156B1 (ar) أميدات عطرية لحمض الكربوكسيليك بصفتها مضادات لمستقبلة البراديكينين b1
PH12016501814A1 (en) Inhibitors of the wnt signalling pathways
BR112015011693A2 (pt) composições fibrinolíticas compreendendo bromelina e nattokinase para a prevenção e tratamento de estados flebotrombóticos
HK1201189A1 (en) Use of amphoteric surfactants for the prevention and treatment of pathogenic vaginal biofilms in vaginal infections
EP2594268A4 (en) ANGIOGENIC INHIBITORY COMPOSITION WITH MACROLACTIN A AND A DERIVATIVELY AS ACTIVE SUBSTANCES
WO2014031982A3 (en) Methods and compositions for treating pain
EA201270547A1 (ru) Фармацевтическая композиция
ECSP16095540A (es) Composiciones antimicrobianas con agentes efervescentes
MA39762A (fr) Nouveaux composés
PL402105A1 (pl) Kompozycja i preparat zawierające tioprolinę i kwas rozmarynowy, zastosowanie tej kompozycji oraz sposób ochrony skóry przed procesem starzenia zewnętrzpochodnego
TR201203085A2 (tr) Sefetamet ve klavulanik asit içeren bileşimler.
TR201203087A2 (tr) Seftibüten ve klavulanik asit formülasyonları.
TN2014000091A1 (en) Amino-substituted imidazopyridazines